Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : Tokyo Joe's Cafe / Societe Anonyme/No Pennies -- Ignore unavailable to you. Want to Upgrade?

To: Rock_nj who wrote (6572)	10/19/1998 1:25:00 PM
From: TokyoMex	Respond to of 119973

WOBURN, Mass.--(BW HealthWire)--July 21, 1998--ANIKA THERAPEUTICS, INC. (Nasdaq:ANIK) today reported that net income for the second quarter ended June 30, 1998 increased to $2,201,000, or $.20 per diluted share, compared with $337,000, or $.04 per diluted share, for the same period last year. Revenues for the second quarter rose 88 percent to $4,596,000 from $2,450,000 for the corresponding quarter in 1997. Book value 3.02 Cash 2.35 TTl .. 5.37 Float 6 mill ..

To: Rock_nj who wrote (6572)	10/19/1998 1:26:00 PM
From: EyeDrMike	Respond to of 119973

gfsa.co.za

To: Rock_nj who wrote (6572)	10/19/1998 1:28:00 PM
From: EyeDrMike	Read Replies (1) \| Respond to of 119973

Anika said it received a letter from the FDA's Center for Devices and Radiological Health stating that the company's pre-market approval application for the product was not approval. The letter found that the data in its clinical trial failed to demonstrate effectiveness according to the study's pre-determined success criteria.